8-K: Dyadic Reports Q3 2025 Results, Pivots to Commercial Focus

Dyadic International, Inc. announced its third-quarter 2025 financial results, highlighting a strategic shift to commercialization and key advancements in its protein production platforms.

Summary

• Dyadic completed a strategic pivot from an R&D-driven company to a commercially focused biotechnology solutions provider.
• The company rebranded as Dyadic Applied BioSolutions and launched a redesigned website to enhance commercial engagement and investor relations.
• Dyadic secured a non-exclusive CRISPR/Cas9 license with ERS Genomics to expand genetic engineering capabilities for strain optimization.
• Cash, cash equivalents, restricted cash, and investment-grade securities increased to approximately $10.4 million as of September 30, 2025, up from $9.3 million at December 31, 2024.
• An underwritten equity offering completed on August 1, 2025, generated approximately $4.9 million in net proceeds.
• Total revenue for Q3 2025 decreased to $1,165,000 compared to $1,958,000 for Q3 2024, primarily due to reduced license and milestone revenue.
• Net loss for Q3 2025 significantly increased to $1,976,000, or $(0.06) per share, compared to $203,000, or $(0.01) per share, for Q3 2024.
• The company advanced multiple recombinant protein programs, including animal-free serum albumin, transferrin, growth factors, and DNase-1, with initial purchase orders received or expected soon.
• Key milestones were achieved in biopharmaceutical programs with funding from the Gates Foundation and CEPI, demonstrating the C1 platform's potential for vaccine and antibody production.

Sentiment

Score: 4

Explanation: While the company has made significant strategic progress in pivoting to a commercial focus, securing key licenses, and advancing multiple product candidates, the financial results for Q3 2025 show a substantial increase in net loss and a decrease in revenue. The capital raise improved liquidity but also caused dilution. The long-term potential from the commercialization efforts and partnerships is notable, but the current financial performance warrants caution.

Positives

• Completed a strategic pivot from an R&D focus to a commercial focus, aiming for scalable growth.
• Rebranded as Dyadic Applied BioSolutions and launched a redesigned website optimized for commercial engagement and investor relations.
• Secured a non-exclusive CRISPR/Cas9 license with ERS Genomics to enhance genetic engineering capabilities and accelerate strain optimization.
• Strengthened liquidity and cash position, with cash, cash equivalents, restricted cash, and investment-grade securities totaling $10.4 million as of September 30, 2025, up from $9.3 million at December 31, 2024.
• Completed an underwritten equity offering on August 1, 2025, raising approximately $4.9 million in net proceeds.
• Received first purchase orders in the cell culture media and molecular biology reagent segments.
• Advanced multiple recombinant protein programs, including animal-free serum albumin (expected commercial launch late 2025/early 2026), recombinant transferrin (initial purchase orders expected by end of 2025), and recombinant FGF (initial purchase orders received in October 2025).
• Received a $0.5 million milestone payment from Proliant in October 2025, bringing total payments to $1.5 million to date.
• Received a $250,000 milestone payment from Inzymes for productivity achievements for a second enzyme, bringing total payments to $1.275 million.
• A peer-reviewed publication validated the C1 platform for producing SARS-CoV-2 spike protein, demonstrating comparable performance to mammalian cell-derived antigens.
• Achieved key milestones in biopharmaceutical collaborations with the Gates Foundation (receiving approximately $2.4 million from a $3 million grant) and CEPI (eligible for up to $2.4 million from a $4.5 million grant).

Negatives

• Total revenue for the three months ended September 30, 2025, decreased by 40.5% to $1,165,000 from $1,958,000 in the same period a year ago.
• Net loss for the three months ended September 30, 2025, increased significantly by 872% to $1,976,000, or $(0.06) per share, compared to $203,000, or $(0.01) per share, for the same period a year ago.
• Loss from operations for Q3 2025 increased to $1,925,000 compared to $203,000 for Q3 2024.
• Research and development revenue decreased by $183,000 due to a reduction in active collaborations.
• License and milestone revenue decreased by $1,425,000 from the Proliant and Inzyme agreements compared to the prior year.
• Research and development expenses increased to $572,000 from $460,000 due to a rise in internal research initiatives.
• General and administrative expenses increased to $1,481,000 from $1,298,000, reflecting increases in rebranding and business development expenses.

Risks

• History of net losses.
• Market and regulatory acceptance of microbial protein production platforms and other technologies.
• Failure to commercialize microbial protein production platforms or other technologies.
• Competition, including from alternative technologies.
• Results of nonclinical studies and clinical trials.
• Capital needs.
• Changes in global economic and financial conditions.
• Reliance on information technology.
• Dependence on third parties.
• Government regulations and environmental, social, and governance issues.
• Intellectual property risks.
• Ability to comply with the listing standards of the Nasdaq Stock Market LLC.

Future Outlook

Dyadic anticipates the commercial launch of animal-free serum albumin in late 2025 or early 2026, with ongoing revenue sharing from Proliant sales expected in 2026. Initial purchase orders for recombinant transferrin and DNase-1 are expected by the end of 2025, alongside continued optimization and data generation for nucleic acid enzymes into 2026. Sampling for Alpha-Lactalbumin and Human Lactoferrin is projected for early 2026, and scale-up for Inzymes' first enzyme is targeting a late 2025 or early 2026 launch. The company believes it is well positioned for sustainable revenue growth and long-term value creation.

Management Comments

• "During the third quarter, Dyadic completed its strategic pivot from a research and development-driven company to a commercially focused biotechnology solutions provider underpinned by our protein production platforms."
• "With our comprehensive rebranding, redesigned website optimized for commercial engagement and investor relations, and the addition of CRISPR technology through our ERS Genomics license, we are strengthening the foundation for scalable growth."
• "Our third-quarter achievements demonstrate the successful execution of our strategic transformation to a commercial biotech leader. With enhanced capabilities from our CRISPR license, growing commercial traction, and a strengthened financial foundation, we believe Dyadic is well positioned for sustainable revenue growth and long-term value creation."

Industry Context

Dyadic's strategic pivot to commercialization and focus on precision-engineered, animal-free proteins aligns with growing industry demand for sustainable and scalable biomanufacturing solutions. Its expansion into non-animal cell culture media, diagnostics, and nutrition markets addresses the increasing need for high-quality, cost-effective alternatives to animal-derived products, particularly in biopharma and cell/gene therapy manufacturing. Collaborations with global health initiatives like the Gates Foundation and CEPI for low-cost vaccines and antibodies position Dyadic within the broader trend of developing accessible biotherapeutics. The partnership with Intralink to expand in Japan and South Korea targets rapidly growing biopharma markets in Asia.

Comparison to Industry Standards

• The C1-produced SARS-CoV-2 spike protein demonstrated comparable structure, stability, and immunogenicity to mammalian cell-derived antigens, highlighting the platform's competitive potential for vaccine manufacturing.
• Dyadic's animal-free transferrin performed consistently with leading recombinant reference standards in cell proliferation testing for animal muscle cell growth.
• Recombinant Fibroblast Growth Factor (FGF) showed comparable efficacy to reference standards in supporting animal muscle cell growth.
• Early data from the Gates Foundation collaboration indicate C1-produced monoclonal antibodies (mAbs) perform comparably to mAbs produced from traditional CHO cell lines, suggesting the C1 platform can offer a competitive alternative for biotherapeutic production.

Related Party Transactions

• Interest expense related party was $(28,176) for the three months ended September 30, 2025, compared to $(39,344) for the same period a year ago.
• Convertible notes, net of issuance costs related party, totaled $2,058,569 as of September 30, 2025, compared to $1,065,876 as of December 31, 2024.

Stakeholder Impact

• Shareholders experienced dilution from the August 1, 2025, equity offering of 6,052,000 shares and an increased net loss per share.
• Customers are expected to benefit from new and advanced animal-free protein products, expanded online ordering capabilities, and enhanced genetic engineering services.
• Partners (e.g., Proliant, Inzymes, Fermbox Bio, Gates Foundation, CEPI) continue to engage in collaborations, indicating ongoing development and potential for shared commercial success.
• Employees may see stable or growing opportunities in R&D and commercialization efforts due to increased internal research initiatives and strategic pivot.

Next Steps

• Commercial launch of animal-free serum albumin in late 2025 or early 2026.
• Anticipated ongoing revenue sharing from Proliant sales in 2026.
• Expected initial purchase orders for recombinant transferrin and DNase-1 by the end of 2025.
• Expanding validation efforts for recombinant transferrin for diagnostic, research, and cell culture uses.
• Ongoing optimization and validation of recombinant growth factors.
• Expected additional improvements and data for nucleic acid enzymes through late 2025 and into 2026.
• Sampling for Alpha-Lactalbumin and Human Lactoferrin for research and nutritional markets expected early 2026.
• Scale-up and commercialization efforts for Inzymes' first enzyme progressing toward a late 2025 or early 2026 launch.
• Ongoing negotiations in the biomass processing, biofuels, and pulp & paper markets for EN3ZYME.
• Hosting an earnings call on November 12, 2025, at 5:00 pm ET.

Key Dates

Recommendation

While Dyadic has made significant strategic progress in pivoting to a commercial focus, securing key licenses, and advancing multiple product candidates, the financial results for Q3 2025 show a substantial increase in net loss and a decrease in revenue. The capital raise improved liquidity but also caused dilution. The long-term potential from the commercialization efforts and partnerships is notable, but the current financial performance warrants caution. Investors should hold to observe if the strategic pivot translates into tangible revenue growth and reduced losses in the coming quarters.

Keywords

Biotechnology, Recombinant proteins, C1 platform, Dapibus platform, Animal-free proteins, CRISPR, Cell culture media, Vaccine antigens, Enzymes, Financial results, Q3 2025, Dyadic Applied BioSolutions, NASDAQ: DYAI